Artiva Biotherapeutics, Inc. ARTV Increase (Decrease) in Other Receivables

Increase (Decrease) in Other Receivables at other companies

ADTRAN Holdings, Inc.ADTN

$3.31M+190%

ACM ResearchACMR

$406K+106%

State StreetSTT

$313M+26.7%

Moelis & CompanyMC

-$347K-102%

AnterixATEX

-$2.93M—

NWN

Northwest NaturalNWN

-$21.66M-39.6%

Other financials

Income statement

See full

Revenue-—

Operating income-$24.4M-10.2%

Net income-$23.5M-15.8%

EPS (diluted)-$0.95-14.5%

Balance sheet

See full

Cash & equivalents$21.4M-30.6%

Total debt$10.3M-26.7%

Total equity$87.8M-48.0%

Total assets$106.0M-44.6%

Cash flow

See full

Operating cash flow-$21.0M-5.6%

CapEx$242.0K-52.6%

Free cash flow-$21.2M-4.1%

Valuation

See full

Market cap$429.03M+1,015%

Enterprise value$417.88M+1,832%

Profitability

See full

Operating margin-83.9%—

Net margin-79.3%—

Returns & leverage

See full

Return on equity-67.9%—

Debt / equity0.1×0.0×

Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s increase (decrease) in other receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s increase (decrease) in other receivables?: Artiva Biotherapeutics, Inc. (ARTV) reported increase (decrease) in other receivables of -$67K in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s increase (decrease) in other receivables changed year-over-year?: Artiva Biotherapeutics, Inc.'s increase (decrease) in other receivables decreased by 176.1% year-over-year, from $88K to -$67K.